EGFR and neoplasm: Moreover, rebiopsy of tumor tissue demonstrated that EGFR-TKI administration was related to changes in the tumor microenvironment, resulting in a reduced proportion of anti-tumoral CD8+ and FOSP3+ tumor-infiltrating lymphocytes, increased PD-L1 expression, and tumor mutation burden (11).